Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ivacaftor. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR known ✓ | P13569 | 20/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 1.00 |
| ▸ | ADRB3 | P13945 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 1/20 | 1.00 |
| ▸ | AGTR1 | P30556 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | PTGS2 | P35354 | 1/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ivacaftor SCHEMBL29357389 | 1.00 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL29379239 | 1.00 | CFTR (1.00) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL31157966 | 0.99 | CFTR (0.98) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL2100895 | 0.99 | CFTR (0.98) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL18393755 | 0.99 | CFTR (0.98) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL19107543 | 0.96 | CFTR (0.92) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL2102583 | 0.96 | CFTR (0.92) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Deutivacaftor SCHEMBL15504743 | 0.96 | CFTR (0.92) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Ivacaftor SCHEMBL15504751 | 0.96 | CFTR (0.92) | CFTRADORA3ADRB3TBXA2RSLC6A2 | |
| Deutivacaftor SCHEMBL29378674 | 0.96 | CFTR (0.92) | CFTRADORA3ADRB3TBXA2RSLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1952 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2819670-B1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATION THEREOF | VERTEX PHARMA (US) | 2026-05-20 | — | — | EP | claimed |
| EP-4472635-B1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | PROTEOSTASIS THERAPEUTICS INC (US) | 2026-03-19 | — | — | US | claimed |
| US-12458635-B2 | Pharmaceutical composition and administrations thereof | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-11-04 | — | — | US | claimed |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-10-30 | — | — | US | claimed |
| US-20250255819-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | VERTEX PHARMA (US) | 2025-08-14 | — | — | US | claimed |
| EP-3925607-B9 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MEDIATED DISEASES | VERTEX PHARMA (US) | 2025-07-16 | — | — | EP | claimed |
| US-20250221971-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | VERTEX PHARMA (US) | 2025-07-10 | — | — | US | claimed |
| US-RE50453-E1 | Indole derivatives as CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-06-10 | — | — | US | claimed |
| EP-4556008-A2 | PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF CFTR MEDIATED DISEASES | Vertex Pharmaceuticals Incorporated (US) | 2025-05-21 | — | — | EP | claimed |
| US-20090247468-A1 | Spray drying a drug such as telaprevir; VX 770 is excluded; including a non-volatile or high boiling solvent during spray drying of a drug can improve the properties of resulting product | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-10-01 | — | — | US | claimed |
| US-7553855-B2 | Compositions of N-[2,4-bis(1,1-dimethylethyl)-5-hydroxyphenyl]-1,4-dihydro-4-oxoquinoline-3-carboxamide | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-30 | — | — | US | claimed |
| US-7495103-B2 | Modulators of ATP-binding cassette transporters | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-02-24 | — | — | US | claimed |
| EP-2001497-A2 | PHARMACEUTICAL COMPOSITIONS | Vertex Pharmaceuticals, Inc. (US) | 2008-12-17 | — | — | EP | claimed |
| EP-1993360-A2 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | Vertex Pharmaceuticals Incorporated (US) | 2008-11-26 | — | — | EP | claimed |
| US-20080090864-A1 | COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-04-17 | — | — | US | claimed |
| WO-2007079139-A9 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMA (US) | 2007-11-29 | — | — | WO | claimed |
| WO-2007109605-A2 | PHARMACEUTICAL COMPOSITIONS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2007-09-27 | — | — | WO | claimed |
| US-20070218012-A1 | Spray drying a drug such as telaprevir; VX 770 is excluded; including a nonvolatile solvent during spray drying of a drug can improve the properties of resulting product | VERTEX PHARMACEUTICASLS, INC. | 2007-09-20 | — | — | US | claimed |
| WO-2007079139-A2 | SOLID FORMS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | VERTEX PHARMACEUTICALS, INC. (US) | 2007-07-12 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250221971-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | CFTR 1/4885ADORA3 845/4885ADRB3 246/4885 |
| US-12458635-B2 | Pharmaceutical composition and administrations thereof | CYP3A5, CYP4B1, CYP3A4 | CFTR 299/4885ADORA3 461/4885ADRB3 593/4885 |
| US-20250332151-A1 | METHODS OF TREATMENT FOR CYSTIC FIBROSIS | CFTR, SLC26A4, SLC26A3 | CFTR 1/4885ADORA3 645/4885ADRB3 258/4885 |
| US-20090247468-A1 | Spray drying a drug such as telaprevir; VX 770 is excluded; including a non-volatile or high boiling solvent during spray drying of a drug can improve the properties of resulting product | ACE, DPP4, TMPRSS4 | CFTR 72/4885ADORA3 3728/4885ADRB3 1841/4885 |
| US-20070218012-A1 | Spray drying a drug such as telaprevir; VX 770 is excluded; including a nonvolatile solvent during spray drying of a drug can improve the properties of resulting product | ACE, DPP4, TMPRSS6 | CFTR 194/4885ADORA3 3226/4885ADRB3 2015/4885 |
| US-20260078136-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS FOR MODULATING CFTR | CFTR, SCNN1B, SCNN1A | CFTR 1/4885ADORA3 1391/4885ADRB3 1259/4885 |
| US-20250255819-A1 | PHARMACEUTICAL COMPOSITION AND ADMINISTRATIONS THEREOF | CFTR, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, KCNQ5 | CFTR 1/4885ADORA3 1656/4885ADRB3 1048/4885 |
| US-20080090864-A1 | COMPOSITIONS OF N-[2,4-BIS(1,1-DIMETHYLETHYL)-5-HYDROXYPHENYL]-1,4-DIHYDRO-4-OXOQUINOLINE-3-CARBOXAMIDE | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, OPRM1, GRIN2C | CFTR 2134/4885ADORA3 1605/4885ADRB3 994/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.